Furthermore, other research showed that the blockade of C5aR1 in combination with the blockade of PD-1 could restore antitumor immune responses, inhibit tumor cell growth, and improve the outcomes of patients with lung cancer (Ajona et al., 2017). Here, C5AR1 is linked to lung cancer.